Harris, A.L.

mmi 270b food intake intake patient peak plasma levels fasted plasma level study pharmacokinetic state drug exposure exposure effect inhibitor 600 mg cancer ic 50 fasted state limit matrix result rotterdam treatment blood cgs 27023 fasted /fed study novartis pharma ag dose levels confidence university hospital rotterdam phase i peak plasma level light breakfast target inhibition rotterdam cancer institute phase matrix metalloproteinase inhibitor analysis parameter concentration sample spearman difference capsule metalloproteinase ratio ingestion light plasma levels 1.25 times 30 min plasma concentrations administration influence value target pharmacokinetic study alanine aminotransferase t test 90 min range change anticancer treatment day 2 temperatures 25 c interval methods eligibility criteria extracellular matrix degradation introduction mmps 2 department time difference fed-fasted wbc 4.109/ l netherland version 5. x five-ml blood samples criteria eskens @oncd 2 hospital novarti